Corporate Profile

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical dedicated to developing novel treatments for rare diseases associated with the PPi-Adenosine Axis, a critical pathway regulating mineralization and vascular health. Disruptions in this pathway lead to severe conditions such as ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis and ossification of the posterior longitudinal ligament (OPLL). Inozyme’s lead product candidate, INZ-701, is an enzyme replacement therapy (ERT) designed to correct these disruptions. By addressing pathologic mineralization and intimal proliferation, INZ-701 targets the underlying causes of significant morbidity and mortality in these devastating diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

Stock Quote

Press Releases


Jul 02, 2024
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Jun 21, 2024
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
May 30, 2024
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference